Difficulty: Medium
Average Score: 64%
Practice
Which of the following does not produce hypertensive crisis when coadministered with levodopa?
Correct answer
B
Rationale
In the context of pharmacology, particularly in the treatment of Parkinson's disease, understanding the interactions of levodopa with other drugs is crucial. Levodopa is often used in combination with MAO-B inhibitors like selegiline to enhance its efficacy and reduce the required dose, minimizing side effects.
The correct answer, option B - Selegiline, does not produce a hypertensive crisis when coadministered with levodopa because it is a selective MAO-B inhibitor at usual doses. MAO-B inhibitors like selegiline are considered safer in combination with levodopa compared to non-selective MAO inhibitors.
The incorrect options (A) Phenelzine, (C) Isocarboxazid, and (D) Pargyline are non-selective MAO inhibitors. When combined with levodopa, these non-selective MAO inhibitors can lead to the accumulation of tyramine, causing a hypertensive crisis known as the "cheese effect." This highlights the importance of choosing the appropriate MAO inhibitor when coadministering with levodopa.
Educationally, this question emphasizes the significance of understanding drug interactions, especially in the context of Parkinson's disease treatment. It reinforces the idea that not all MAO inhibitors interact with levodopa in the same way and underscores the need for precision in pharmacological decisions to avoid potentially dangerous outcomes for patients.
The correct answer, option B - Selegiline, does not produce a hypertensive crisis when coadministered with levodopa because it is a selective MAO-B inhibitor at usual doses. MAO-B inhibitors like selegiline are considered safer in combination with levodopa compared to non-selective MAO inhibitors.
The incorrect options (A) Phenelzine, (C) Isocarboxazid, and (D) Pargyline are non-selective MAO inhibitors. When combined with levodopa, these non-selective MAO inhibitors can lead to the accumulation of tyramine, causing a hypertensive crisis known as the "cheese effect." This highlights the importance of choosing the appropriate MAO inhibitor when coadministering with levodopa.
Educationally, this question emphasizes the significance of understanding drug interactions, especially in the context of Parkinson's disease treatment. It reinforces the idea that not all MAO inhibitors interact with levodopa in the same way and underscores the need for precision in pharmacological decisions to avoid potentially dangerous outcomes for patients.